Home
CHUYÊN ĐỀ
Issue: Số 73 (2016)
Article
Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Phan Tuấn Đạt: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Published: May 1, 2016
Views: 163
References
1.
1. Yusufs, Zhao F, Mehta SR, Chrolavicius s, Tognoni G, FoxKK. Eff ects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
2.
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to aspirin and fi brinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-89.
3.
3. Chen ZM, Jiang LX, Chen YP. Addition of Clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-21.
4.
4. Mehta SR, Bassand JP, Chrolavicius s, et al. Dose comparisons of Clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930-42.
5.
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15.
6.
6. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus Clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297- 309.
7.
7. BonacaMP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-44 e5.
8.
8. Baigent c, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-60.
9.
9. Gurbel PA, Bilden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the eff ect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
10.
10. Bonello L, Armero s, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010; 56:1630-36.
11.
11. PriceMJ,BergerPB, Teirstein PS, et al. Standard- vs high-dose Clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097-105
12.
12. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl JMed 2009; 360: 354-62.
13.
13. Wiviott SD, TrenkD, Frelinger AL, et al. Prasugrel compared with highloangding and maintenance dose clopidogrelinpatientswithplannedpercutaneouscoronaryintervention: the prasugrelin comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116; 2923-32
14.
14. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of
15.
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 130: e344-e426.
16.
15. Hamm CW, Bassand JP, Agewall s, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart /2011; 32:2999-3054.
17.
16. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST- segment elevation. Eur Heart J 2012; 33:2569 - 619.
18.
17. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
19.
18. Mahaff ey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544-54.
20.
19. Boneỉlo L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014; 63: 872-77.
21.
20. Bellemain-Appaix A, O’Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308:2507-16.
22.
21. Bhatt DL, FoxKA, Hacke w, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-17.
23.
22. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug¬eluting stents. N Engl J Med 2014; 371:2155-66.
24.
23. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107-15.
25.
24. Held c, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.JAm Coll Cardiol 2011; 57:672-84.
26.
25. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefi t with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. / Am Coll Cardiol 2012; 60: 388-96.